KOL Insight - Migraine

This report explores the evolving landscape of migraine therapies, focusing on the insights gathered from key opinion leaders across the US and Europe. It examines the clinical efficacy of anti-CGRP monoclonal antibodies and the growing role of oral gepants in migraine management. This report also addresses key unmet needs in both acute and chronic migraine treatment, compares the effectiveness of various therapeutic options, and highlights promising drug candidates in the early-stage pipeline.

Gain a comprehensive understanding of current and future treatment pathways, including the impact of recent guideline changes on the use of Botox and targeted biological therapies. Additionally, the report provides an analysis of clinical trials with the potential to reshape treatment practices, offering valuable perspectives for pharmaceutical professionals engaged in migraine research and development.

Key Questions Answered:

• 1. What are the main objectives and limitations of current migraine therapies?
• 2. What are the key unmet needs in acute and chronic migraine treatment?
• 3. How have Botox and targeted biological therapies evolved recently?
• 4. How do mAbs and oral gepants compare for migraine prevention?
• 5. What are the concerns with oral ditans for acute migraine treatment?
• 6. Which clinical trials could change migraine treatment practices?
• 7. What studies can enhance the uptake of specific migraine therapies?
• 8. Which early-stage drug candidates show promise for migraine management?

Key Brands:

Partial List of Participating Experts:

• Professor of Neurology, UCLA School of Medicine, Los Angeles, CA, USA.
• Professor of Neurology, Director of Headache Medicine, Yale University, New Haven, CT, USA.
• Associate Professor of Neurology, Jefferson Headache Clinic, Thomas Jefferson University, Philadelphia, PA, USA.
• Neurologist, Hospital da Luz Headache Centre, Lisbon, Portugal.
• Professor of Neurology, Headache and Pain Unit, IRCCS-University of San Raffaele, Rome, Italy.
• Professor of Neurology, Hopital Neurologique Pierre Wertheimer, Lyon, France.

Methodology

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.